Stockscreener 앱 받기
799.08
0.62%
4.89
시장 영업 전:
792.00
-7.08
-0.89%
전일 마감가:
$794.19
열려 있는:
$782.44
하루 거래량:
893.76K
Relative Volume:
0.96
시가총액:
$82.27B
수익:
$14.92B
순이익/손실:
$4.42B
주가수익비율:
19.47
EPS:
41.0422
순현금흐름:
$3.79B
1주 성능:
-3.55%
1개월 성능:
+4.78%
6개월 성능:
+2.23%
1년 성능:
+37.61%
1일 변동 폭
$779.08
$802.78
1주일 범위
$779.08
$839.94
52주 변동 폭
$541.00
$847.00
리제네론 파마슈티컬스 Stock (REGN) Company Profile
명칭
Regeneron Pharmaceuticals Inc
전화
(914) 847-7000
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
799.08 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
544.52 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
1,031.66 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
140.34 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
205.57 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-31 | 재개 | Piper Sandler | Overweight |
| 2026-03-06 | 개시 | Barclays | Overweight |
| 2026-01-07 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2025-12-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | 개시 | HSBC Securities | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-14 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-30 | 다운그레이드 | Argus | Buy → Hold |
| 2025-05-30 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-09-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 개시 | Bernstein | Outperform |
| 2024-01-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 재확인 | Oppenheimer | Perform |
| 2023-06-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-23 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2023-01-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-09 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-09-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-03 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-12-07 | 재개 | Cowen | Market Perform |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 재개 | BMO Capital Markets | Outperform |
| 2021-11-05 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 개시 | H.C. Wainwright | Buy |
| 2021-01-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-01-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-10-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-07-09 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-05-26 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-04-17 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 개시 | The Benchmark Company | Hold |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-26 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-11 | 업그레이드 | Argus | Hold → Buy |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-16 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-12-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 개시 | SunTrust | Hold |
| 2019-11-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
모두보기
리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스
Regeneron Pharmaceuticals (REGN) Wins Pasatru Approval, Is The Upside Already Priced In? - simplywall.st
Did You Lose Money on Regeneron Pharmaceuticals, Inc. (REGN)? Levi & Korsinsky Urges Investors to Act Before September 14, 2026 - ACCESS Newswire
IBBQ vs. PBE: Which Biotech ETF Is the Better Buy? - The Motley Fool
Why Is Regeneron (NASDAQ:REGN) Drawing Attention After Market Drop? - Kalkine Media
Wealthfront Advisers LLC Invests $4.37 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron stock holds above $826 as FDA approval and lawsuit reshape risk picture - Ad-hoc-news.de
Tocqueville Asset Management L.P. Acquires Shares of 3,315 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Madison Asset Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Ceredex Value Advisors LLC Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Diversify Advisory Services LLC Buys New Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Enters New Healthcare Focus - Kalkine Media
Regeneron stock jumps on FDA approval for ultra-rare bone disorder drug - Ad-hoc-news.de
REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals Securities Class ActionContact SueWallSt - Morningstar
Advanz Looks To Nix Regeneron, Bayer Eye Med Patents - Law360
Regeneron Pharmaceuticals (REGN) Wins FDA Approval For The First Adult FOP Treatment - simplywall.st
Regeneron to challenge Ipsen as FDA clears bone disease drug - BioPharma Dive
Regeneron Secures FDA Approval for Rare Genetic Disorder Drug - Yahoo Finance
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REGN Looks 5.6% Undervalued on GF Value™ Amid FDA Approval Boost - GuruFocus
REGN Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regeneron Pharmaceuticals Securities LawsuitContact Levi & Korsinsky - Business Wire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesREGN - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - PR Newswire
Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug - Benzinga
REGENERNON PHARMACEUTICALS, INC. (REGN) SHAREHOLDER ALERT - GlobeNewswire
FDA nod for Regeneron’s Pasatru for ultra-rare genetic disorder FOP - The Pharma Letter
Johnson Financial Group Inc. Buys Shares of 3,250 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
1,311 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Meeder Advisory Services Inc. - MarketBeat
E Fund Management Co. Ltd. Makes New $3.22 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
DCF Advisers LLC Purchases New Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
US FDA approves Regeneron's rare bone disorder drug - Reuters
Regeneron (REGN) Stock Looks Undervalued On Expanded Cancer Collaboration News - Yahoo Finance
REGN Stockholders Interested in Leading the Class Action Against Regeneron Pharmaceuticals, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses - Morningstar
Regeneron (REGN) Results Review: Profit Per Share Clears Its Benchmark in the Current Update; Closing Reaction - Vinanet
TLX: Revenue up 22% to $477.3M, net profit $38.3M, boosted by U.S. sales and Regeneron deal - TradingView
US FDA approves Regeneron’s rare bone disorder drug - KELO-AM
Ninth Circuit Revives Regeneron Kickback Whistleblower Lawsuit - Bloomberg Law News
Pasatru’s FDA Approval Puts Regeneron’s Rare-Disease Playbook To The Test - insights.citeline.com
Regeneron Announces Investor Conference Presentations - marketscreener.com
Why Does Regeneron Pharmaceuticals (NASDAQ:REGN) Merit A Fresh Look? - Kalkine Media
REGN Looks 4.9% Undervalued on GF Value™ After FDA Approval - GuruFocus
Regeneron Pharmaceuticals Wins US FDA Approval For Pasatru In Ultra-Rare Musculoskeletal Condition - marketscreener.com
FDA approves Regeneron’s Pasatru for rare bone disorder FOP - Investing.com
FDA approves Regeneron’s Pasatru for rare bone disorder FOP By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals Announces FDA Approval of Pasatru for Adults With Fibrodysplasia Ossificans Progressiva - Quiver Quantitative
Regeneron rare bone disorder therapy approved (REGN:NASDAQ) - Seeking Alpha
REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action NoticeContact Levi & Korsinsky - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Regeneron - GlobeNewswire
Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 52-Week HighWhat's Next? - MarketBeat
Regeneron Pharmaceuticals stock hits 52-week high at 821.41 USD By Investing.com - Investing.com Australia
Regeneron Pharmaceuticals stock hits 52-week high at 821.41 USD - Investing.com
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
리제네론 파마슈티컬스 (REGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
리제네론 파마슈티컬스 주식 (REGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Fenimore Christopher R. | EVP Finance CFO |
Aug 18 '26 |
Option Exercise |
381.92 |
6,283 |
2,399,603 |
24,583 |
| Guarini Kathryn | Director |
Aug 10 '26 |
Option Exercise |
719.37 |
400 |
287,748 |
1,003 |
| Guarini Kathryn | Director |
Aug 10 '26 |
Sale |
800.00 |
400 |
320,000 |
603 |
| Zoghbi Huda Y | Director |
Aug 10 '26 |
Option Exercise |
376.69 |
800 |
301,352 |
2,503 |
| Zoghbi Huda Y | Director |
Aug 10 '26 |
Sale |
800.00 |
800 |
640,000 |
1,703 |
0.83%
1.11%
자본화:
|
볼륨(24시간):